Materias dentro de su búsqueda.
Mostrando 541 - 560 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.31s Limitar resultados
  1. 541
    “…OBJECTIVES: To describe the radiological phenotype of HER2-mutant lung cancers on CT at presentation. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    CT features of HER2-mutant lung adenocarcinomas
  2. 542
    “…Interestingly, HER2 was required for EBOVΔVP30-induced TYRO3 and AKT1 activation, but the other TAM receptors (TYRO3 and MERTK) were not essential for EBOVΔVP30-induced HER2 and AKT1 activation. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2-mediated enhancement of Ebola virus entry
  3. 543
    “…Human EGF Receptor 2 (HER2) is an important oncogene driving aggressive metastatic growth in up to 20% of breast cancer tumors. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
  4. 544
    “…HER3 is called ‘pseudokinase’ because it undergoes heterodimerization and forms dimers such as HER2-HER3 and HER1 (EGFR)-HER3. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Radiolabeled HER3 Targeting Molecules for Tumor Imaging
  5. 545
    “…This paper presents these issues of oppression, colonisation, language and agency, making it difficult for these groups to contribute to the current management of oceans and coasts, and asks scientists and practitioners in this space to be allies and enable the needed shift to earth’s guardians taking a leading role in nurturing her for our future.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Empowering her guardians to nurture our Ocean’s future
  6. 546
    por Jennings, Julia, Clark, Jennifer L.
    Publicado 2021
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Educational Case: HER-2 Positive Breast Cancer
  7. 547
    Publicado 1852
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    California—Her Hospitals—Prevalent Diseases—Mortality, &c.
  8. 548
    “…SIGNIFICANCE: HER3 is an actionable target in prostate cancer, especially with anti-HER3 immunoconjugates, and targeting HER3 warrants clinical evaluation in prospective trials.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER3 Is an Actionable Target in Advanced Prostate Cancer
  9. 549
    “…Human epidermal growth factor receptor 2 (HER2/neu) is an oncogenic driver and a proven target for treatment of breast and gastric cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Review of the Role of HER2/neu in Colorectal Carcinomas
  10. 550
    “…SIMPLE SUMMARY: The aim of this work is to elucidate the role of immune response in HER2+ breast cancer. By describing the principal components of the tumour microenvironment and its interaction with the known and novel anti-HER2 targeted therapies, this review summarizes the ways immune modulators could be implemented in clinical practice. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immunological Landscape of HER-2 Positive Breast Cancer
  11. 551
    “…SIMPLE SUMMARY: HER3 is a member of the HER family. In the past decade, HER3 has been recognized as an important protein in allowing tumors to grow unchecked. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER3 Alterations in Cancer and Potential Clinical Implications
  12. 552
    “…SIMPLE SUMMARY: A wide range of treatments are available for HER2-positive breast cancer, which have greatly improved the prognosis and quality of life of these patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immunotherapies against HER2-Positive Breast Cancer
  13. 553
    “…Most CEs occurred during anti-HER2 therapy (123; 77.4%) and were asymptomatic or mildly symptomatic decreases in LVEF (133; 83.6%). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
  14. 554
    “…CONCLUSIONS: HER2 IHC(3+) BC displays a higher pCR rate than HER2 IHC(2+)/FISH-positive BC (p ≤ 0.05), with a positive correlation between the HER2 protein expression levels and the response to anti-HER2 therapy.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy
  15. 555
    “…BACKGROUND: The phase II neo-adjuvant clinical trial ICORG10-05 (NCT01485926) compared chemotherapy in combination with trastuzumab, lapatinib or both in patients with HER2+ breast cancer. We studied circulating immune cells looking for alterations in phenotype, genotype and cytotoxic capacity (direct and antibody-dependent cell-mediated cytotoxicity (ADCC)) in the context of treatment response. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy
  16. 556
    “…Recent trials provide evidence that HER2 is a potential new target for patients with colorectal cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC)
  17. 557
    “…Introduction: This study aimed to compare the efficacy and safety of docetaxel + trastuzumab + pertuzumab and docetaxel + carboplatin + trastuzumab + pertuzumab for treating HER2-positive breast cancer. Method: HER2-positive breast cancer from patients diagnosed between January 2020 and September 2022 were included in this retrospective study. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
  18. 558
    “…Overexpression of HER-2/neu in human breast carcinomas correlates with poor prognosis, although its strength as a prognostic indicator varies widely in different reports. …”
    Enlace del recurso
    Enlace del recurso
    Texto
    Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
  19. 559
    “…METHODOLOGY AND PRINCIPAL FINDINGS: In this study, we demonstrate that lapatinib, a dual TKI of EGFR and HER2 downregulates TS via inhibition of the nuclear translocation of EGFR and HER2. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
  20. 560
    Enlace del recurso
    Enlace del recurso
    Texto
    Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer
Herramientas de búsqueda: RSS